RE: above 9p10 Aug 2021 15:24
some posts of the recent past:
MrsApeslaptop
30 Jul '21 - 11:03 - 7483
I posted this on the other place. But 1802 is worth 50p to £2 on its own as its unique.
Reference point for a preclinical IL-2 inhibitor that is not unique.
hxxps://www.evaluate.com/vantage/articles/news/deals/merck-gets-treg-train-pandion-buy
The-Oracle
SUPERIOR to a miracle drug01 Aug 2021 15:13
Just a thought from what Stoney posted earlier.
We are SUPERIOR, NOT just better.
"On 01 July, Sareum announced that the proof of concept experiments had been completed and importantly that their kinase inhibitor drug candidate SDC-1801 had reduced the levels of cytokines associated with ARDS in human lung cells infected with SARS-CoV-2 and demonstrated a profile that was considered superior to dexamethasone. This is great news for not only the UK but for the World."
Just been playing on my mind, the aspect of something superior being near enough available, yet no one paying attention during a pandemic. Something must be going on, it's far to quiet from Sareum.
https://ownsnap.com/sareum-holdings-sar-l-shares-show-300-growth-this-year-covid-19-will-push-shares-up-again/
BasilAlderman
RE: Sareum FOMO =10p+ today. A Great launch pad for 20p nextToday 07:33
Sareum now has a very realistic opportunity of achieving 20p soon before moving up another x1 to 40p a share. It is pretty obvious that the latest HNWI buyng £1million Sareum shares a few days ago isn't investing to make a paltry 10% gain. They will no doubt be wanting to make at least 5 - 10 million profit from their £1 million investment in Sareum. That would suggest that they have a share price of 40p - 70p in mind. i.e. a £1billion+ price tag. Interestingly, Kymab (co-founded by Sareum NED Dr Owen) was sold for a similar amount to Sanoffi earlier this year.